gap-134 and Atrial-Fibrillation

gap-134 has been researched along with Atrial-Fibrillation* in 1 studies

Other Studies

1 other study(ies) available for gap-134 and Atrial-Fibrillation

Article	Year
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents. Bioorganic & medicinal chemistry letters, 2009, Aug-15, Volume: 19, Issue:16 In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R(1)=OH, R(2)=NH(2)), a compound currently under clinical evaluation. Selected compounds with the desired in-vitro profile demonstrated positive in vivo results in the mouse CaCl(2) arrhythmia model upon oral administration. Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Benzamides; Disease Models, Animal; Dogs; Drug Discovery; Gap Junctions; Mice; Proline; Rats; Structure-Activity Relationship; Tachycardia, Ventricular	2009

Article

Year

Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents.

Bioorganic & medicinal chemistry letters, 2009, Aug-15, Volume: 19, Issue:16

In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R(1)=OH, R(2)=NH(2)), a compound currently under clinical evaluation. Selected compounds with the desired in-vitro profile demonstrated positive in vivo results in the mouse CaCl(2) arrhythmia model upon oral administration.

Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Benzamides; Disease Models, Animal; Dogs; Drug Discovery; Gap Junctions; Mice; Proline; Rats; Structure-Activity Relationship; Tachycardia, Ventricular

2009